billion dollar industry, huh. Where are the sales numbers? Its approved in AU and EU but have they been able to get a patient try their device?
in one of your earlier posts, you said so. I checked their website, and it doesn't say they are manufacturing the API.
Yes they do sell Rizatriptan Tablets but does that make them the API manufacturer?
Have you gone through the questions for the advisory panel?
Try to answer as many questions as you can by looking at the data. Yo will come to know what's coming tomorrow.
If you haven't , do it. You still have 2 hours i guess.
No position here. Gud Luck to all.
That's true in-fact. Read it again. They FINISHED THE LAST QUARTER with only $131.5 million. The cash was raised after the quarter 1 finished. The $233 million is on pro-forma basis (cash + recent raise)
LOVAZA NRx going down is most likely due to the launch of genreric Lovaza by Teva.
What about Trilipix ?
Endocyte - ECYT 100mn$ invested at $21-22 in April, now at 6.3$
Tekmira - TKMR 56mn$ invested at $28.5 in March, now at 12.13$
can't think big huh? do you have an idea what this thing is worth?
have a look at Folate-Aminopterin, and come with your revised guesstimates.
Dare or care to clarify what you are saying?
I have laid out my point with enough reasoning. Can you?
Don't get me wrong but even Vinta+PLD was curative (refer their analyst day presentation of 2013 or 2012)
If anyone is going to attend the meeting, ask this on my behalf:
Have you been receiving interest from potential partners for co-development of Aldoxorubicin ? OR
Are you exploring strategic alternatives like partnership or acquisition of the company?
AZN is a powerhouse. Yet acquired OMTH and now facing lawsuit from AMRN as AMRN holds the IP for OMTH's product.
Moral: Powerhouse can do the mistakes.